Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

57results about How to "Inhibit overexpression" patented technology

Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

It has been discovered that the stimulation of beta-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising beta-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by beta-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of beta-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium / calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
Owner:MASSACHUSETTS INST OF TECH

Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

It has been discovered that the stimulation of beta-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising beta-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by beta-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of beta-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium / calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
Owner:MASSACHUSETTS INST OF TECH

Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library application to the detection of mycobacteria

InactiveUS6183957B1Reducing potential for recombinationAvoiding lethal overexpressionSugar derivativesMicrobiological testing/measurementNucleotideGenomic DNA
The present invention relates to a method for isolating a polynucleotide of interest that is present in the genome of a first mycobacterium strain and / or is expressed by the first mycobacterium strain, where the polynucleotide of interest is also absent or altered in the genome of a second mycobacterium strain and / or is not expressed in the second mycobacterium. The method comprises: (a) contacting the genomic DNA of the first mycobacterium strain under hybridizing conditions with the DNA of a least one clone that belongs to a bacterial artificial chromosome (BAC) genomic DNA library of the second mycobacterium strain, and (b) isolating the polynucleotide of interest that does not form a hybrid with the DNA of the second mycobacterium strain. This invention further pertains to a Mycobacterium tuberculosis strain H37Rv genomic DNA library, as well as a Mycobacterium bovis BCG strain Pasteur genomic DNA library, and the recombinant BAC vectors that belong to those genomic DNA libraries. This invention also relates to a method, as well as a kit, for detecting a nucleic acid of a mycobacterium in a biological sample.
Owner:INST PASTEUR

Use of salt of an acetylsalicylic acid for the treatment of viral infections

The invention relates to a method of use of a composition comprising a salt of the o-acetylsalicylic acid with a basic amino acid for producing a pharmaceutical composition for the prophylaxis or treatment of viral infections of humans or of animals, in particular mammals and birds.
Owner:ASPIAIR GMBH

Cytokine receptor modulators, method of identifying same, and method of modulating cytokine receptors activity with same

The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and / or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed. Also disclosed are methods for treating patients with a disease or condition associated with abnormal cytokine receptor mediated function or activity such as inflammatory, autoimmune and vascular diseases.
Owner:VALO HSJ PARTNERSHIP

Novel pyridazinone BTK inhibitor as well as preparation and application thereof

The invention belongs to the field of medical chemistry, relates to a novel pyridazinone BTK inhibitor as well as preparation and application thereof, in particular to a pyridazinone BTK inhibitor, apreparation method thereof, a pharmaceutical composition containing the same, and application thereof to treatment of Bruton's tyrosine kinase-related diseases.
Owner:NANJING ADVANCED BIOLOGICAL MATERIALS & PROCESS EQUIP INST CO LTD

Pyridazinone BTK inhibitors and application thereof

The invention relates to the field of medicinal chemistry, relates to pyridazinone BTK inhibitors and an application thereof, and concretely relates to pyridazinone BTK inhibitors represented by formula (I), a preparation method thereof, a medicinal composition containing the compounds, and a use of the compounds or the medicinal composition in the treatment of Bruton's tyrosine kinase-related diseases.
Owner:NANJING ADVANCED BIOLOGICAL MATERIALS & PROCESS EQUIP INST CO LTD

Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a bac-based DNA library: application to the detection of mycobacteria

InactiveUS6492506B1Reducing potential for recombinationInhibit overexpressionSugar derivativesBacteriaCDNA libraryNucleotide
A method for isolating a polynucleotide of interest that is present in the genome of a first mycobacterium strain and / or is expressed by the first mycobacterium strain, where the polynucleotide of interest is also absent or altered in the genome of a second mycobacterium strain and / or is not expressed in the second mycobacterium. The method includes (a) contacting the genomic DNA of the first mycobacterium strain under hybridizing conditions with the DNA of a least one clone that belongs to a bacterial artificial chromosome (BAC) genomic DNA library of the second mycobacterium strain, and (b) isolating the polynucleotide of interest that does not form a hybrid with the DNA of the second mycobacterium strain. This invention further pertains to a Mycobacterium tuberculosis strain H37Rv genomic DNA library, as well as a Mycobactetium bovis BCG strain Pasteur genomic DNA library, and the recombinant BAC vectors that belong to those genomic DNA libraries. This invention also relates to mycobacterial nucleic acids, and methods and kits for using these nucleic acids to detect mycobacteria in a biological sample.
Owner:INST PASTEUR

Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor

Disclosed are a method for treating an aging-related disease and a method for screening a therapeutic agent for an aging-related disease. The method for treating an aging-related disease includes administering to a subject a progerin expression inhibitor as an active ingredient. The method for screening a therapeutic agent for an aging-related disease includes selecting a candidate drug inhibitory of progerin expression.
Owner:PUSAN NAT UNIV IND UNIV COOPERATION FOUND +1

Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis, and preparation method thereof

The invention belongs to the field of Chinese medicines, and relates to a Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis and a preparation method thereof. On the basis of the theory of 'body resistance weakened while pathogenic factors prevailing, insufficiency of Qi and blood, and blood stasis and collaterals obstruction' in traditional Chinese medical science, the Chinese medicinal compound preparation is prepared from Chinese medicines such as Danshen root, angelica sinensis, peach kernel, twotooth achyranthes root and processed rhubarb. Through animal experiment and clinical trial, the Chinese medicinal compound preparation can improve renal haemodynamics, adjust lipid metabolic disturbance, enhance oxidation resistance, and inhibit over expression of cell factors so as to improve glomerulosclerosis and interstitial fibrosis degree, protect residual renal structures and functions, and delay the process of early-stage and medium-stage chronic renal failure deterioration. The Chinese medicinal compound preparation is particularly suitable for treating patients who suffer from chronic kidney disease (CKD2-4) and renal fibrosis which comprise renal insufficiency, proteinuria, atrophy of kidney and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M

Gold nanoparticle based protease imaging probes and use thereof

InactiveUS8551727B2Rapidly screen activation and inhibitionInhibit overexpressionPowder deliveryNanostructure manufactureDiseasePeptide substrate
Disclosed are a metal nanoparticle onto which a peptide substrate specifically degraded by protease and fluorophore are chemically modified for selectively imaging protease expressed in cell and in tissue in a human body, and the use thereof. Also, a quantitative analysis method of protease using the metal nanoparticle, a cell imaging method and a drug screening method of inhibiting a protease overexpression are provided. In detail, the present invention is directed to a metal nanoparticle having a peptide substrate and fluorophore coupled thereto, the peptide substrate and the fluorophore being specifically degraded by due to a protease activated in various ways in cell and in a human body to exhibit fluorescence. Hence, the metal nanoparticle can be used to rapidly screen activation and inhibition of the protease in the imaging manner. Also, the metal nanoparticle is capable of being selectively absorbed into a cell and a tissue so as to be possibly used as a sensor for real-time cell imaging and early diagnosis of non-invasive diseases.
Owner:KOREA INST OF SCI & TECH

Bacillus subtilis having effects of relieving enteritis and promoting development of intestines and application

ActiveCN110144310ARepair and enhance mucosal barrier functionEffective in treating inflammatory bowel diseaseMilk preparationBacteriaBacterial strainInflammation
The invention relates to bacillus subtilis having effects of relieving enteritis and promoting development of intestines. The bacillus subtilis is named as RZ001, the category name is Bacillus subtilis., the preservation No. is CGMCC NO:17116, the preservation date is 7, January, 2019, the preservation address is No.3, No. 1 Courtyard, Beichen West Road, Chaoyang District, Beijing, and the preservation unit is China General Microbiological Culture Collection Center(CGMCC). The bacterial strain has the functions of repairing and strengthening mucosal barrier, has the function of treating inflammatory and allergic dermatosis enteritis, and can also promote the development of the intestines. The bacterial strain is hopeful to be used for preparing drugs and fermented foods for preventing andtreating intestine inflammation and promoting development, and has broad application prospect.
Owner:TIANJIN UNIV OF SCI & TECH

Composition for treating psoriasis and preparation method thereof

The invention discloses a natural compound for treating psoriasis, a composition of the compound, and a preparation method and application of a nano liposome gel (referred to as: AKBA-Lip) of the compound and the composition.
Owner:SUZHOU BOTANY BIOMEDICALS

Recombinant koi herpesvirus (KHV) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi

The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and to a vaccine for preventive and / or therapeutic treatment of a disease caused by koi herpesvirus (KHV) or CyHV-3. The 5 recombinant herpesvirus is used to confer immunity on fish, preferably on carps, more preferably on Cyprinus carpio, against a disease caused by koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3).
Owner:UNIV LIEGE

Method for manufacturing phenolic acid positions of vernonia anthelmintica and anti-inflammation application of phenolic acid positions

The invention relates to a method for manufacturing phenolic acid positions of vernonia anthelmintica and anti-inflammation application of the phenolic acid positions. The method includes smashing dried fruits of the vernonia anthelmintica; extracting extracts by the aid of organic solvents; separating and purifying the extracts by the aid of resin to obtain the phenolic acid positions of the vernonia anthelmintica. Main active ingredients of phenolic acid at the positions of the vernonia anthelmintica include 3, 4-dicaffeoyl-quinic acid, 3, 5-dicarffeoyl-quinic acid and 4, 5-dicaffeoyl-quinic acid, the total content of the phenolic acid ranges from 20% to 99%, excess release of nitric oxide of inflammation mediators can be obviously suppressed by the phenolic acid positions of the vernonia anthelmintica in inflammation response of mice macrophage RAW264.7 induced by lipopolysaccharide, excessive secretion of interleukin 6, interleukin 1 and tumor necrosis factors alpha of inflammation factors can be suppressed, excess expression of nitric oxide synthase and epoxidase 2 can be suppressed, and phosphorylation of nuclear factors kB can be suppressed. The method has the advantages that the phenolic acid positions of the vernonia anthelmintica has excellent anti-inflammation activity and can be used for preventing or treating inflammation due to the excess nitric oxide, the excess tumor necrosis factors alpha, the excess interleukin 6 or the excess interleukin 1.
Owner:XINJIANG TECHN INST OF PHYSICS & CHEM CHINESE ACAD OF SCI

Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor

Disclosed are a method for treating an aging-related disease and a method for screening a therapeutic agent for an aging-related disease. The method for treating an aging-related disease includes administering to a subject a progerin expression inhibitor as an active ingredient. The method for screening a therapeutic agent for an aging-related disease includes selecting a candidate drug inhibitory of progerin expression.
Owner:PUSAN NAT UNIV IND UNIV COOPERATION FOUND +1

Novel application of oleanolic acid

The invention relates to the field of medicines, in particular relates to novel application of oleanolic acid and especially relates to application of preparation of a medicine for inhibiting skin inflammations. An experiment shows that the oleanolic acid can be used for effectively inhibiting the release of inflammatory factors, so that the inflammation diminishing aim is realized. The result shows that the oleanolic acid can be used for preparing a skin inflammation inhibitor.
Owner:WUYI UNIV +1

Application of marine-derived oligoguluronic acid

The invention relates to the field of biological medicine, and discloses an application of marine-derived oligoguluronic acid. MdOA obtained by oxidation and degradation of sodium alginate can inhibit excessive NO production by an RAW264.7 cell induced by LPS, and the inhibition effect is concentration-dependent. According to the application, by adoption of an RT-PCR method, it is found that over-expressed mRNAs of iNOS and COX-2 in the RAW264.7 cell are reduced along with the increase of MdOA stimulation time and the relationship is concentration-dependent. By adoption of a Western Blot method, it is found that overexpression of iNOS protein and COX-2 protein can be inhibited by the MdOA. By adoption of an ELISA method, it is found that the MdOA can inhibit expression of intracellular related inflammatory cytokines comprising TNF-alpha, IL-6, IL-1beta, and the like. Therefore, the marine-derived oligoguluronic acid MdOA can be used for preparation of anti-inflammatory medicines.
Owner:DALIAN SHENLAN PEPTIDE TECH R & D CO LTD

Paclitaxel and nitrophthalazinone BTK (Bruton 's tyrosine kinase) inhibitor combined pharmaceutical composition and application thereof

The invention provides a paclitaxel and nitrophthalazinone BTK (Bruton 's tyrosine kinase) inhibitor combined pharmaceutical composition, comprising: an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is composed of paclitaxel and a BTK inhibitor represented by the formula (I); the mole ratio of the paclitaxel to the BTK inhibitor represented by the formula (I) in the active ingredient is (0.14-0.20):1. The pharmaceutical composition can be used for preparing a medicament for preventing and / or treating a disease associated with Bruton's tyrosine kinase, and the therapeutic effect is good.
Owner:NANJING ADVANCED BIOLOGICAL MATERIALS & PROCESS EQUIP INST CO LTD

Burn cream for treating burn and scald and its preparation method

The present invention relates to a burn ointment for treating burns and scalds and the preparation method thereof, which pertains to the Chinese traditional patent medicines and the preparation technical field, the present invention aims at solving the technical problem of: providing the burn ointment which can promote the wound healing as soon as possible, prevent the wound infection, prevent and reduce the scar formation and the preparation method thereof. The parts by weight of the raw materials of the burn ointment are: champion bauhinia: 15 to 90; anoectochilus formosanus: 3 to 18; stearate: 1 to 10; glycerol stearate: 0.2 to 2; sesame oil: 2 to 20; liquid paraffin: 1 to 10; beeswax: 1 to 10; glycerol: 3 to 30; triethanolamine: 0.15 to 1.5; ethyl paraben: 0.01 to 0.2; distilled water: 5 to 50; borneol: 0.02 to 0.5. The preparation method is that the base materials are added in proportion after the pretreatments of powder making and solvent extraction according to the different characteristics of raw materials, so as to prepare the ointment. The external application of the present invention has the treatment effects of rapid pain stopping, fast wound healing, strong anti-infective ability and no scars, furthermore the use is convenient, the operation is simple and the cost is low.
Owner:福建中医学院

Boron-containing compound, pharmaceutical composition and preparation method and application of boron-containing compound

The invention discloses a boron-containing compound, a pharmaceutical composition and a preparation method and application of the boron-containing compound. The boron-containing compound has a generalstructural formula (I), and nucleotide substances serve as small molecules required by DNA synthesis and are easily taken up by rapidly proliferating tumor cells in a large amount, so that 10B atomscombined with the nucleotide substances enter the nucleus of tumor cells together, and the boron-containing compound can kill tumors more effectively after neutron irradiation. Secondly, the boron agent synthesized by the compound belongs to an epidermal growth factor receptor (EGFR) inhibitor, produces synergistic tumor growth inhibition effect with BNCT, competitively blocks ATP (adenosine triphosphate) and receptor tyrosine kinase domain to inhibit EGFR overexpression effect, prevents DNA repair of tumor cells, and further inhibits growth, migration, differentiation and survival of the tumor cells.
Owner:童永彭

Application of baohuoside I in preparation of drug for preventing and treating cerebral arterial thrombosis

The invention discloses application of baohuoside I in preparation of a drug for preventing and treating cerebral arterial thrombosis. The baohuoside I is adopted to prepare a drug for preventing and treating cerebral arterial thrombosis. The prepared pharmaceutical composition has a protective role on acute cerebral arterial thrombosis by verification of a series of animal experiments, and the measurement is associated with the baohuoside I for stopping reduction of PPARalpha and PPARgamma expression, and inhibiting of activation of an IkB / NF-kB channel, so as to inhibit overexpression of inflammatory factors such as 1L-1beta, TGFbeta1 and the like.
Owner:ZUNYI MEDICAL UNIVERSITY

Cytokine receptor modulators and method of modulating cytokine receptor activity

The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and / or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed. Also disclosed are methods for treating patients with a disease or condition associated with abnormal cytokine receptor mediated function or activity such as inflammatory, autoimmune and vascular diseases.
Owner:VALO HSJ PARTNERSHIP

Quinazoline compounds

Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compounds can effectively inhibit the overexpression and / or overactivity of epidermal growth factor receptor (EGFR).
Owner:HUTCHISON MEDIPHARMA LTD

Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis, and preparation method thereof

The invention belongs to the field of Chinese medicines, and relates to a Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis and a preparation method thereof. On the basis of the theory of 'body resistance weakened while pathogenic factors prevailing, insufficiency of Qi and blood, and blood stasis and collaterals obstruction' in traditional Chinese medical science, the Chinese medicinal compound preparation is prepared from Chinese medicines such as Danshen root, angelica sinensis, peach kernel, twotooth achyranthes root and processed rhubarb. Through animal experiment and clinical trial, the Chinese medicinal compound preparation can improve renal haemodynamics, adjust lipid metabolic disturbance, enhance oxidation resistance, and inhibit over expression of cell factors so as to improve glomerulosclerosis and interstitial fibrosis degree, protect residual renal structures and functions, and delay the process of early-stage and medium-stage chronic renal failure deterioration. The Chinese medicinal compound preparation is particularly suitable for treating patients who suffer from chronic kidney disease (CKD2-4) and renal fibrosis which comprise renal insufficiency, proteinuria, atrophy of kidney and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M

Paclitaxel and fluoropyridazine BTK (Bruton 's tyrosine kinase) inhibitor combined pharmaceutical composition and application thereof

The invention provides a paclitaxel and fluoropyridazine BTK (Bruton 's tyrosine kinase) inhibitor combined pharmaceutical composition, characterized by comprising: an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is composed of paclitaxel and a BTK inhibitor represented by the formula (I); the mole ratio of the paclitaxel to the BTK inhibitor represented by the formula (I) in the active ingredient is (0.14-0.20):1. The pharmaceutical composition can be used for preparing a medicament for preventing and / or treating a disease associated with Bruton's tyrosine kinase, and the therapeutic effect is good.
Owner:NANJING ADVANCED BIOLOGICAL MATERIALS & PROCESS EQUIP INST CO LTD

Taxol and novel nitrophthalazinone BTK inhibitor combined pharmaceutical composition and application thereof

The invention provides a taxol and novel nitrophthalazinone BTK inhibitor combined pharmaceutical composition, which consists of an active ingredient and pharmaceutically acceptable adjuvants, whereinthe active ingredient is composed of taxol and a BTK inhibitor shown as formula (I) (as shown in Description); and the mole ratio of the taxol to the BTK inhibitor shown as formula (I) in the activeingredient is at (0.14-0.20) to 1. The pharmaceutical composition can be used for preparing medicines for preventing and / or treating diseases related to Bruton's tyrosine kinase, with a good therapeutic effect.
Owner:NANJING ADVANCED BIOLOGICAL MATERIALS & PROCESS EQUIP INST CO LTD

Intestinal tract contrast agent for X-ray barium enema examination and preparation method of intestinal tract contrast agent

The invention belongs to the technical field of traditional Chinese medicines, and relates to an intestinal tract contrast agent for X-ray barium enema examination. The intestinal tract contrast agentfor X-ray barium enema examination consists of the following raw materials in parts by weight: 200-250 grams of barium sulfate, 70-90 grams of a traditional Chinese medicine composition and a properamount of water. A traditional Chinese medicine extract is prepared from the following raw material components: Radix Astragali, Semen Coicis, Radix Angelicae Dahuricae, Radix Sangusorbae, Radix Scutellariae, Radix Puerariae, Herba Euphorbiae Humifusae, Radix Saposhnikoviae, and Radix Bupleuri. The preparation method comprises the following steps: pulverizing, soaking, decocting and filtering thetraditional Chinese medicine raw materials to obtain liquid medicine; decocting the liquid medicine, carrying out ultrasonic treatment on the liquid medicine, and carrying out centrifugal separation to obtain supernatant; and blending the liquid medicine with the supernatant to obtain the traditional Chinese medicine composition. The intestinal tract contrast agent for X-ray barium enema examination has the advantages that intestinal filling effect is good, clear development is implemented, meanwhile, a lower gastrointestinal mucous membrane is protected, chronic colitis is treated, the medicine can directly reach a diseased region, and meanwhile, a local washing and cleaning effect can further be achieved to achieve purposes of stopping diarrhea and diminishing inflammation, relaxing themuscular spasm and stopping pain, improving local blood circulation and metabolism, enhancing an intestinal immune function and facilitating ulcer healing.
Owner:郝润松 +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products